| Allgood, P. C., Warwick, J., Warren, R. M., Day, N. E., & Duffy, S. W. A case-control study of the impact of the East Anglian breast screening programme on breast cancer mortality, Br J Cancer, vol. 98, no. 1, pp. 206-209. |
| Almonte, M., Albero, G., Molano, M., Carcamo, C., Garcia, P. J., & Perez, G. Risk factors for Human Papillomavirus Exposure and Co-factors for Cervical Cancer in Latin America and the Caribbean, Vaccine, vol. 26, p. L16-L36. |
| Arbyn, M. & Cuzick, J. International agreement to join forces in synthesizing evidence on new methods for cervical cancer prevention., Cancer Lett.. |
| Arbyn, M. & Cuzick, J. The Beijing Cochrane Workshop on cervical cancer prevention: Cytology versus HPV-based cervical cancer screening., Central European Journal of Public Health, vol. 16, no. S, pp. 27-28. |
| Attard, G., Clark, J., Ambroisine, L., Fisher, G., Kovacs, G., Flohr, P., Berney, D., Foster, C. S., Fletcher, A., Gerald, W. L., Moller, H., Reuter, V., De Bono, J. S., Scardino, P., Cuzick, J., & Cooper, C. S. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer, Oncogene, vol. 27, no. 3, pp. 253-263. |
| Attard, G., Clark, J., Ambroisine, L., Mills, I. G., Fisher, G., Flohr, P., Reid, A., Edwards, S., Kovacs, G., Berney, D., Foster, C., Massie, C. E., Fletcher, A., De Bono, J. S., Scardino, P., Cuzick, J., Cooper, C. S., & Transatlantic Prostate Group. Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer, Br J Cancer, vol. 99, no. 2, pp. 314-320. |
| Bosch, F. X., Franco, E. L., Herrero, R., Munoz, N., Cuzick, J., Garland, S. M., Stanley, M., & Wright, T. C. A scientific response to prevent cervical cancer in the world [Preface], Vaccine, vol. 26, p. V-VI. |
| Bowen, R., Duffy, S., Ryan, D., Hart, I., & Jones, L. Reply: Early onset breast cancer in black British women: a letter to the editor of British Journal of Cancer regarding early onset of breast cancer in a group of British black women, British Journal of Cancer, vol. 98, no. 8, pp. 1483-1484. |
| Bowen, R. L., Duffy, S. W., Ryan, D. A., Hart, I. R., & Jones, J. L. Early onset of breast cancer in a group of British black women, British Journal of Cancer, vol. 98, no. 2, pp. 277-281. |
| Bray, F. & Parkin, D. M. Evaluation of data quality in the cancer registry: Principles and methods. Part 1: Comparability, validity and timeliness., Eur J Cancer. |
| Cafferty, F. H., Sasieni, P. D., & Duffy, S. A deterministic model for estimating the reduction in colorectal cancer incidence due to endoscopic surveillance., Statistical Methods in Medical Research. |
| Carozzi, F., Confortini, M., Dalla Palma, P., Del Mistro, A., Gillio-Tos, A., De Marco, L., Giorgi-Rossi, P., Pontenani, G., Rosso, S., Sani, C., Sintoni, C., Segnan, N., Zorzi, M., Cuzick, J., Rizzolo, R., & Ronco, G. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial, Lancet Oncology, vol. 9, no. 10, pp. 937-945. |
| Cassidy, A., Myles, J. P., van Tongeren, M., Page, R. D., Liloglou, T., Duffy, S. W., & Field, J. K. The LLP risk model: an individual risk prediction model for lung cancer, BRIT J CANCER, vol. 98, no. 2, pp. 270-276. |
| Ciatto, S., Houssami, N., Martinelli, F., Bonardi, R., Cafferty, F. H., & Duffy, S. W. Second breast cancers in a Tuscan case series: characteristics, prognosis, and predictors of survival, British Journal of Cancer, vol. 99, no. 3, pp. 539-544. |
| Clark, J., Attard, G., Jhavar, S., Flohr, P., Reid, A., De Bono, J., Eeles, R., Scardino, P., Cuzick, J., Fisher, G., Parker, M. D., Foster, C. S., Berney, D., Kovacs, G., & Cooper, C. S. Complex patterns of ETS gene alteration arise during cancer development in the human prostate, Oncogene, vol. 27, no. 14, pp. 1993-2003. |
| Cuzick, J. Chemoprevention of breast cancer, Breast Cancer, vol. 15, no. 1, pp. 10-16. |
| Cuzick, J., Szarewski, A., Mesher, D., Cadman, L., Austin, J., Perryman, K., Ho, L., Terry, G., Sasieni, P., Dina, R., & Soutter, W. P. Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology-Results from the Hammersmith study, Int.J Cancer, vol. 122, no. 10, pp. 2294-2300. |
| Cuzick, J. Aromatase inhibitors in early breast-cancer treatment: The story so far, Breast, vol. 17S3, pp. 2-8. |
| Cuzick, J. IBISII: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole, Expert Review of Anticancer Therapy, vol. 8, no. 9, pp. 1377-1385. |
| Cuzick, J. Hormone replacement therapy and the risk of breast cancer, European Journal of Cancer, vol. 44, no. 16, pp. 2344-2349. |
| Cuzick, J., Arbyn, M., Sankaranarayanan, R., Tsu, V., Ronco, G., Mayrand, M. H., Dillner, J., & Meijer, C. J. L. M. Overview of Human Papillomavirus-Based and Other Novel Options for Cervical Cancer Screening in Developed and Developing Countries, Vaccine, vol. 26, p. K29-K41. |
| Cuzick, J., Sestak, I., Cella, D., & Fallowfield, L. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial, Lancet Oncology, vol. 9, no. 12, pp. 1143-1148. |
| Cuzick, J. "Use of aromatase inhibitors in breast cancer prevention", 3 edn, PERGAMON-ELSEVIER SCIENCE LTD, St Gallen, SWITZERLAND, p. 21. |
| Cuzick, J. Routine audit of large-scale cervical cancer screening programs, J Natl Cancer Inst, vol. 100, no. 9, pp. 605-606. |
| Cuzick, J. Primary endpoints for randomised trials of cancer therapy, Lancet, vol. 371, no. 9631, pp. 2156-2158. |
| Cuzick, J. Use of LHRH-agonists as adjuvant therapy for breast cancer, Expert Opin Ther Targets, vol. 12, no. 8, pp. 1065-1071. |
| Derchain, S. F., Sarian, L. O., Naud, P., Roteli-Martins, C., Longatto-Filho, A., Tatti, S., Branca, M., Erzen, M., Serpa-Hammes, L., Matos, J., Gontijo, R. C., Braganca, J. F., Lima, T. P., Maeda, M. Y. S., Lorincz, A., Dores, G. B., Costa, S., Syrjanen, S., & Syrjanen, K. Safety of screening with Human papillomavirus testing for cervical cancer at three-year intervals in a high-risk population: experience from the LAMS study, J Med Screen, vol. 15, no. 2, pp. 97-104. |
| Dillner, J., Rebolj, M., Birembaut, P., Petry, K. U., Szarewski, A., Munk, C., de Sanjose, S., Naucler, P., Lloveras, B., Kjaer, S., Cuzick, J., van Ballegooijen, M., Clavel, C., & Iftner, T. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study, British Medical Journal, vol. 337, no. 7676. |
| Dillner, L., Pagliusi, S., Bray, F., Lorincz, A., Kjaer, S. K., Anttila, A., Iversen, O. E., Dillner, J., Lehtinen, M., & Paavonen, J. Strengthening prevention programs to eliminate cervical cancer in the Nordic countries, ACTA OBSTET GYN SCAN, vol. 87, no. 5, pp. 489-498. |
| Dowsett, M., Allred, C., Knox, J., Quinn, E., Salter, J., Wale, C., Cuzick, J., Houghton, J., Williams, N., Mallon, E., Bishop, H., Ellis, I., Larsimont, D., Sasano, H., Carder, P., Cussac, A. L., Knox, F., Speirs, V., Forbes, J., & Buzdar, A. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial, J Clin Oncol., vol. 26, no. 7, pp. 1059-1065. |
| Du Toit, G., Katz, Y., Sasieni, P., Mesher, D., Maleki, S. J., Fisher, H. R., Fox, A. T., Turcanu, V., Amir, T., Zadik-Mnuhin, G., Cohen, A., Livne, I., & Lack, G. Early consumption of peanuts in infancy is associated with a low prevalence of peanut allergy, Journal of Allergy and Clinical Immunology, vol. 122, no. 5, pp. 984-991. |
| Duffy, S. W., Olsen, A. H., Gabe, R., Tabar, L., Warwick, J., Fielder, H., Tryggvadottir, L., & Agbaje, O. F. Screening opportunity bias in case-control studies of cancer screening, Journal of Applied Statistics, vol. 35, no. 5, pp. 537-546. |
| Duffy, S. W., Lynge, E., Jonsson, H., Ayyaz, S., & Olsen, A. H. Complexities in the estimation of overdiagnosis in breast cancer screening, British Journal of Cancer, vol. 99, no. 7, pp. 1176-1178. |
| Duffy, S. W., Nagtegaal, I. D., Astley, S. M., Gillan, M. G. C., Mcgee, M. A., Boggis, C. R. M., Wilson, M., Beetles, U. M., Griffiths, M. A., Jain, A. K., Johnson, J., Roberts, R., Deans, H., Duncan, K. A., Iyengar, G., Griffiths, P. M., Warwick, J., Cuzick, J., & Gilbert, F. J. Visually assessed breast density, breast cancer risk and the importance of the craniocaudal view, Breast Cancer Research, vol. 10, no. 4. |
| Duffy, S. W., Nagtegaal, I. D., Wallis, M., Cafferty, F. H., Houssami, N., Warwick, J., Allgood, P. C., Kearins, O., Tappenden, N., O'Sullivan, E., & Lawrence, G. Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival, Am J Epidemiol, vol. 168, no. 1, pp. 98-104. |
| Eastell, R., Adams, J. E., Coleman, R. E., Howell, A., Hannon, R. A., Cuzick, J., Mackey, J. R., Beckmann, M. W., & Clack, G. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230, J Clin Oncol., vol. 26, no. 7, pp. 1051-1057. |
| Eastham, J. A., Kattan, M. W., Fearn, P., Fisher, G., Berney, D. M., Oliver, T., Foster, C. S., Moller, H., Reuter, V., Cuzick, J., & Scardino, P. Local progression among men with conservatively treated localized prostate cancer: results from the transatlantic prostate group, Eur.Urol., vol. 53, no. 2, pp. 347-354. |
| Field, J. K. & Duffy, S. W. Lung cancer screening: the way forward, British Journal of Cancer, vol. 99, no. 4, pp. 557-562. |
| Flores, Y. N., Bishai, D. M., Shah, K. V., Lazcano-Ponce, E., Lorincz, A., Hernindez, M., Ferris, D., & Salmeron, J. Risk factors for cervical cancer among HPV positive women in Mexico, SALUD PUBLICA MEXICO, vol. 50, no. 1, pp. 49-58. |
| Forbes, J. F., Cuzick, J., Buzdar, A., Howell, A., Tobias, J. S., & Baum, M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial, Lancet Oncol., vol. 9, no. 1, pp. 45-53. |
| Franco, E. L. & Cuzick, J. Cervical cancer screening following prophylactic human papillomavirus vaccination, Vaccine, vol. 26, no. Supplement 1, p. A16-A23. |
| Garland, S. M., Cuzick, J., Domingo, E. J., Goldie, S. J., Kim, Y. T., Konno, R., Parkin, D. M., Qiao, Y. L., Sankaranarayanan, R., Stern, P. L., Tay, S. K., & Bosch, F. X. Recommendations for Cervical Cancer Prevention in Asia Pacific, Vaccine, vol. 26, p. M89-M98. |
| Geary, J., Sasieni, P., Houlston, R., Izatt, L., Eeles, R., Payne, S. J., Fisher, S., & Hodgson, S. V. Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC), Familial Cancer, vol. 7, no. 2, pp. 163-172. |
| Gilbert, F. J., Astley, S. M., Gillan, M. G. C., Agbaje, O. F., Wallis, M. G., James, J., Boggis, C. R. M., & Duffy, S. W. Single reading with computer-aided detection for screening mammography, New England Journal of Medicine, vol. 359, no. 16, pp. 1675-1684. |
| Gilbert, F. J., Astley, S. M., Boggis, C. R. M., Mcgee, M. A., Griffiths, P. M., Duffy, S. W., Agbaje, O. F., Gillan, M. G. C., Wilson, M., Jain, A. K., Barr, N., Beetles, U. M., Griffiths, M. A., Johnson, J., Roberts, R. M., Deans, H. E., Duncan, K. A., & Iyengar, G. Variable size computer-aided detection prompts and mammography film reader decisions, Breast Cancer Research, vol. 10, no. 4. |
| Giordano, L., Webster, P., Anthony, C., Szarewski, A., Davies, P., Arbyn, M., Segnan, N., & Austoker, J. "Guidance on communication with women and health professionals involved in cervical cancer screening," in European guidelines for quality assurance in cervical cancer screening, 2 edn, European Commission. |
| Giordano, L., Webster, P., Anthony, C., Szarewski, A., Davies, P., Arbyn, M., Segnan, N., & Austoker, J. Improving the quality of communication in organised cervical cancer screening programmes, Patient Education and Counseling, vol. 72, no. 1, pp. 130-136. |
| Herrero, R., Ferreccio, C., Salmeron, J., Almonte, M., Sanchez, G. I., Lazcano-Ponce, E., & Jeronimo, J. New Approaches to Cervical Cancer Screening in Latin America and the Caribbean, Vaccine, vol. 26, p. L49-L58. |
| Howell, A., Bundred, N. J., Cuzick, J., Allred, D. C., & Clarke, R. "Response and resistance to the endocrine prevention of breast cancer", United States, pp. 201-211. |
| Jenkins, V. A., Ambroisine, L. M., Atkins, L., Cuzick, J., Howell, A., & Fallowpeld, L. Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II), Lancet Oncology, vol. 9, no. 10, pp. 953-961. |
| Kattan, M. W., Cuzick, J., Fisher, G., Berney, D. M., Oliver, T., Foster, C. S., Moller, H., Reuter, V., Fearn, P., Eastham, J., & Scardino, P. T. Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent, Cancer, vol. 112, no. 1, pp. 69-74. |
| Kudahetti, S., Fisher, G., Ambroidine, I., Kattan, M., Foster, C., Oliver, T., Moller, H., Reuter, V., Fearn, P., Eastham, J., Scardino, P., Cuzick, J., & Berney, D. "Cell-cycle proteins as biomarkers in clinically localised prostate cancer patients managed conservatively-results from the trans-atlantic prostate group", BLACKWELL PUBLISHING, Athens, GREECE, pp. 279-280. |
| Larsen, I. K., Småstuen, M. J. T. B., Langmark, F., Parkin, D. M., Bray, F., & Møller, B. Data quality at the Cancer Registry of Norway: An overview of comparability, completeness, validity and timeliness., Eur J Cancer. |
| Lawrence, G., Wallis, M., Allgood, P., Nagtegaal, I. D., Warwick, J., Cafferty, F. H., Houssami, N., Kearins, O., Tappenden, N., O'Sullivan, E., & Duffy, S. W. Population estimates of survival in women with screen-detected and symptomatic breast cancer taking account of lead time and length bias., Breast Cancer Res Treat. |
| Lorincz, A. "HPV Testing," in Colposcopy Principles and Practice: An Integrated Textbook and Atlas, Apgar BS, Brotzman GL, & Spitzer M, eds., W.B. Saunders Company, Philadelphia, pp. 79-90. |
| Murillo, R., Almonte, M., Pereira, A., Ferrer, E., Gamboa, O. A., Jeronimo, J., & Lazcano-Ponce, E. Cervical Cancer Screening Programs in Latin America and the Caribbean, Vaccine, vol. 26, p. L37-L48. |
| Nazarenko, I., Kobayashi, L., Giles, J., Fishman, C., Chen, G., & Lorincz, A. A novel method of HPV genotyping using Hybrid Capture sample preparation method combined with GP5+/6+ PCR and multiplex detection on Luminex XMAP, J Virol Methods, vol. 154, no. 1-2, pp. 76-81. |
| Oliver, R. T. D., Lorincz, A., & Cuzick, J. "Prostate cancer prevention by short-term antiandrogens: A novel strategy", 3 edn, PERGAMON-ELSEVIER SCIENCE LTD, St Gallen, SWITZERLAND, p. 32. |
| Olsen, A. H., Parkin, D. M., & Sasieni, P. Cancer mortality in the United Kingdom: projections to the year 2025, British Journal of Cancer, vol. 99, no. 9, pp. 1549-1554. |
| Pal, A., Provezano, E., Duffy, S. W., Pinder, S. E., & Purushotham, A. D. A model for predicting non-sentinel lymph node metastatic disease in sentinel lymph node positive patients, Br J Surg, vol. 95, no. 3, pp. 302-309. |
| Parkin, D. M. The role of cancer registries in cancer control, International Journal of Clinical Oncology, vol. 13, no. 2, pp. 102-111. |
| Parkin, D. M., Louie, K. S., & Clifford, G. Burden and trends of type-specific human papillomavirus infections and related diseases in the Asia Pacific region., Vaccine no. Supplement 26, p. M1-M16. |
| Parkin, D. M., Sitas, F., Chirenje, M., Stein, L., Abratt, R., & Wabinga, H. Part I: Cancer in indigenous Africans-Burden, distribution, and trends, Lancet Oncology, vol. 9, no. 7, pp. 683-692. |
| Parkin, D. M. The global burden of urinary bladder cancer, Scandinavian Journal of Urology and Nephrology, vol. 42, pp. 12-20. |
| Parkin, D. M., Tappenden, P., Olsen, A. H., Patnick, J., & Sasieni, P. Predicting the impact of the screening programme for colorectal cancer in the UK., J Med Screen, vol. 15, no. 4, pp. 163-174. |
| Parkin, D. M., Almonte, M., Bruni, L., Clifford, G., Curado, M. P., & Pineros, M. Burden and Trends of Type-Specific Human Papillomavirus Infections and Related Diseases in the Latin America and Caribbean Region, Vaccine, vol. 26, p. L1-L15. |
| Perrett, C. M., Walker, S. L., O'Donovan, P., Warwick, J., Harwood, C. A., Karran, P., & McGregor, J. M. Azathioprine treatment photosensitizes human skin to ultraviolet A radiation, Br J Dermatol, vol. 159, no. 1, pp. 198-204. |
| Perry, N. M., Allgood, P. C., Milner, S. E., Mokbel, K., & Duffy, S. W. Mammographic breast density by area of residence: possible evidence of higher density in urban areas, Curr.Med.Res.Opin., vol. 24, no. 2, pp. 365-368. |
| Perry, N. M., Allgood, P. C., Duffy, S. W., & Mokbel, K. Exposure to traffic emissions throughout life and risk of breast cancer, Cancer Causes Control, vol. 19, no. 4, p. 435. |
| Qiao, Y. L., Sellors, J. W., Eder, P. S., Bao, Y. P., Lim, J. M., Zhao, F. H., Weigl, B., Zhang, W. H., Peck, R. B., Li, L., Chen, F., Pan, Q. J., & Lorincz, A. T. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China, Lancet Oncology, vol. 9, no. 10, pp. 929-936. |
| Ronco, G., Giorgi-Rossi, P., Carozzi, F., Confortini, M., Dalla, P. P., Del Mistro, A., Gillio-Tos, A., Minucci, D., Naldoni, C., Rizzolo, R., Schincaglia, P., Volante, R., Zappa, M., Zorzi, M., Cuzick, J., & Segnan, N. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test, J Natl.Cancer Inst., vol. 100, no. 7, pp. 492-501. |
| Sargent, A., Bailey, A., Almonte, M., Turner, A., Thomson, C., Peto, J., Desai, M., Mather, J., Moss, S., Roberts, C., & Kitchener, H. C. Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial, British Journal of Cancer, vol. 98, no. 10, pp. 1704-1709. |
| Sestak, I., Cuzick, J., Sapunar, F., Eastell, R., Forbes, J. F., Bianco, A. R., & Buzdar, A. U. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis, Lancet Oncology, vol. 9, no. 9, pp. 866-872. |
| Sestak, I., Forbes, J. F., Edwards, R., Howell, A., & Cuzick, J. "Timing and severity of prominent side effects of anastrozole and tamoxifen", 7 edn, PERGAMON-ELSEVIER SCIENCE LTD, Berlin, GERMANY, p. 71. |
| Sherrill, B., Amonkar, M., Wu, Y., Hirst, C., Stein, S., Walker, M., & Cuzick, J. Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer, British Journal of Cancer, vol. 99, no. 10, pp. 1572-1578. |
| Sherrill, B., Amonkar, M., Wu, Y., Hirst, C., Stein, S., Walkers, M., & Cuzick, J. "Disease progression as a predictor of overall survival in metastatic breast cancer: a meta-analysis", 7 edn, PERGAMON-ELSEVIER SCIENCE LTD, Berlin, GERMANY, p. 216. |
| Singh, S., Cuzick, J., Ferguson, S., Blake, G., Truscott, J., Coleman, R., Eastel, R., & Howell, A. "Effect of anastrozole on bone mineral density after one year of treatment: Results from bone sub-study of the International Breast Cancer Prevention Study (IBIS-II)", ELSEVIER SCI LTD, Heriot Watt Univ, Edinburgh, SCOTLAND, p. S53-S54. |
| Sitas, F., Parkin, D. M., Chirenje, M., Stein, L., Abratt, R., & Wabinga, H. Part II: Cancer in indigenous Africans - causes and control, Lancet Oncology, vol. 9, no. 8, pp. 786-795. |
| Smith, R. A., Field, J. K., & Duffy, S. W. A global approach to cancer-screening trials, Lancet Oncology, vol. 9, no. 10, pp. 908-909. |
| Syrjanen, K., Naud, P., Derchain, S., Roteli-Martins, C., Longatto, A., Tatti, S., Branca, M., Erzen, M., Hammes, L. S., Matos, J., Gontijo, R., Sarian, L., Braganga, J., Arlindo, F. C., Maeda, M. Y. S., Lorincz, A., Dores, G. B., Costa, S., & Syrjanen, S. Drug addiction is not an independent risk factor for oncogenic human papillomavirus infections or high-grade cervical intraepithelial neoplasia: case-control study nested within the Latin American Screening study cohort, INT J STD AIDS, vol. 19, no. 4, pp. 251-258. |
| Syrjanen, K., Derchain, S., Roteli-Martins, C., Longatto, A., Hammes, L. S., & Sarian, L. Value of Conventional Pap Smear, Liquid-Based Cytology, Visual Inspection and Human Papillomavirus Testing as Optional Screening Tools Among Latin American Women < 35 and >= 35 Years of Age: Experience from the Latin American Screening Study, Acta Cytologica, vol. 52, no. 6, pp. 641-653. |
| Szarewski, A. Double blind peer review: Response rate was only 7.7%, BMJ, vol. 336, no. 7640, p. 346. |
| Szarewski, A. HPV vaccines: peering through the fog, Journal of Family Planning and Reproductive Health Care, vol. 34, no. 4, pp. 207-209. |
| Szarewski, A., Ambroisine, L., Cadman, L., Austin, J., Ho, L., Terry, G., Liddle, S., Dina, R., McCarthy, J., Buckley, H., Bergeron, C., Soutter, P., Lyons, D., & Cuzick, J. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears, Cancer Epidemiol Biomarkers Prev, vol. 17, no. 11, pp. 3033-3042. |
| Wishart, G. C., Greenberg, D. C., Britton, P. D., Chou, P., Brown, C. H., Purushotham, A. D., & Duffy, S. W. Screen-detected vs symptomatic breast cancer: is improved survival due to stage migration alone?, British Journal of Cancer, vol. 98, no. 11, pp. 1741-1744. |
|
